ReviewAdvances in experimental medicine and biology2026
Emerging Therapeutic Interventions for Treatment‑Resistant Depression.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment-resistant depression (TRD) represents a major clinical challenge and a distinct neurobiological syndrome within affective disorders. This chapter outlines the latest progress in therapeutic strategies, highlighting translational models, precision psychiatry, personalized therapeutic strategies, and computational tools. Traditional pharmacotherapy largely targets monoaminergic systems, especially serotonin, dopamine, and norepinephrine; however, with growing mechanistic insights into additional impairment, precision interventions are becoming feasible but remain constrained by clinical trial design, regulatory barriers, and access disparities. We aim not to revisit established advanced treatment strategies but to disseminate experimental developments that have shown enough promise in preclinical studies to spark scientific curiosity and inspire new TRD management strategies.
Indexed as
Identifiers
42036583What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.